Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.
Also called NCT02393612
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 151 participants
- Sponsor
- Alvogen Korea
- Registry
-
NCT02393612
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02393612. Randomized; triple masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease
- Acronym
- DAVICI
- Condition
- Peripheral Arterial Disease
- Intervention (Drug)
- DP-R202
- Intervention (Drug)
- Anplag tab
- Lead sponsor
- Alvogen Korea
Record details
- Record id
cardio:ct-nct02393612- Content hash
80724831bc0980b22d54db7396775cf921afd844b987a2f2fefa807435ee9cc7